Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Date:4/22/2008

l.

The pivotal study is expected to commence in the first quarter of 2009, with a potential projected BLA filing in late 2010. BioVex is currently commissioning its GMP manufacturing facility in Woburn, Massachusetts, which is intended to provide product for Phase III studies and launch.

Dr Robert Coffin, Chief Technology Officer for BioVex, said:

"This agreement with the FDA for the pivotal Phase III study design for OncoVEX(GM-CSF) in melanoma, which uses a very similar design as successfully employed in Phase II, is a significant event for BioVex. We believe the Phase II study results relating to durable objective response provide a sound basis on which to proceed with confidence to Phase III where the primary objective is to demonstrate a statistically significant increase in durable objective responses as compared to control therapy. We look forward to the presentation of the Phase II results at ASCO, and thereafter to the initiation of the pivotal study."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX(GM-CSF), is an unpartnered, first-in-class oncolytic, or cancer destroying virus technology. OncoVEX(GM-CSF) works by: 1) replicating and spreading within solid tumors, causing the death of cancer cells; while 2) stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. Based on the strength of the clinical data generated to date, coupled with a benign side effect profile, BioVex believes OncoVEX(GM-CSF) has the potential to become a leading standard of care in the treatment of many solid tumors.

OncoVEX(GM-CSF) is currently complet
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Provides Further Comments on the Pivotal Phase III Trials
2. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
3. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
6. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
7. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... "Cancer Biomarker Market by Tumor (Breast, Lung, Prostate) Type ... Immunoassay) Application (Diagnostic, Drug Discovery, Prognostic) & Geography - ... Biomarkers Market is expected to reach around 17,689.0 Million ... the forecast period of 2015 to 2020. ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
(Date:8/28/2015)... 2015 Research and ... the "Investigation Report on China,s Insulin Aspart ... Developed by Novo Nordisk, insulin aspart (under ... drug for the treatment of diabetes. Compared with ... insulin analog, starts working fast and reports higher ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... Study Data in Pediatric Patients,Presented at the ... PARSIPPANY, N.J., Nov. 11 Daiichi Sankyo,Inc. ... pivotal study supporting,the use of colesevelam HCl ... were presented for the first time at ...
... November 11, 2008 at 9:00 am ET, ... (Nasdaq: ANSV ) today announced that the ... of capsaicin, narrowly missed its,primary endpoint of reducing ... four to 32 hours post-surgery. The same,measure was ...
Cached Medicine Technology:Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 6Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 7Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 2Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 3Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 4Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 5
(Date:8/30/2015)... ... August 31, 2015 , ... ... 66th Annual Convention & Expo October 5th & 6th in San Antonio, TX. ... AHCA/NCAL convention brings industry professionals from all over the country come to share ...
(Date:8/30/2015)... ... August 30, 2015 , ... Lizzie’s Lice Pickers ... to school special. The company is currently offering lice head checks for just $10, ... company is offering a 10% discount on their lice treatment products. “With kids returning ...
(Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... ... Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and ... and skin care experience having spent the last 25 years working in operations, ...
(Date:8/29/2015)... , ... August 30, 2015 , ... ... 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , ... a simple digital handwritten signature. , Clinical trial sites can now ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is a ... field in the military. All too often VA hospitals treat patients with harmful and ... the VA program over a decade ago, the reality is that only 10% of ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... Back Chronic Disease,Initiatives, WASHINGTON, Oct. 20 ... many Americans are forgoing basic,medical care in the ... fight against chronic disease and support for care ... sense in tough economic times,--dining out less often ...
... chances of survival, study found , , MONDAY, Oct. 20 (HealthDay ... lymphoma increases if one is poor but decreases if the ... published in the Dec. 1 issue of Cancer , ... that blacks tend to have a higher risk of death ...
... LITTLE ROCK, Ark., Oct. 20 Heifer International, ... perfect,holiday gift alternative for the green-minded client, the ... for tighter gift budgets.,Heifer focuses on doing one ... 2 billion people living on less than $2 ...
... to Offer "Safe and Sober Free Cab Ride Home" , ... Alameda, ... will be adding Halloween to its list of holidays for the Safe ... up with Veterans Cab and Yellow Cab in Alameda and Luxor Cab ...
... member of PPI class for treatment for GERD and Erosive ... ... Company,Limited ("Takeda") today announced that Takeda Global Research and,Development Center, Inc., a ... Drug Administration (FDA) that,the agency will not be able to complete its ...
... Hydrate and Soothe Young Throats, FARMINGDALE, N.Y., ... approaches, Integrated Beverage Group, Ltd. (IBG), a manufacturer,of ... newest,product -- Children,s Throat Cooler(R). This non-medicated ready-to-freeze,liquid ... wish to choose a 100%,drug free product to ...
Cached Medicine News:Health News:Nation's Economic Downturn Threatens Continuity of Care for Chronic Conditions 2Health News:Heifer International: The Greener Good for Holiday Giving 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 3Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: